Tags

Type your tag names separated by a space and hit enter

A systematic review of SARS-CoV-2 vaccine candidates.
Signal Transduct Target Ther. 2020 Oct 13; 5(1):237.ST

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that is highly pathogenic and has caused the recent worldwide pandemic officially named coronavirus disease (COVID-19). Currently, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Vaccines, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, have already entered clinical trials. In this review, we provide an overview of the experimental and clinical data obtained from recent SARS-CoV-2 vaccines trials, and highlight certain potential safety issues that require consideration when developing vaccines. Furthermore, we summarize several strategies utilized in the development of vaccines against other infectious viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), with the aim of aiding in the design of effective therapeutic approaches against SARS-CoV-2.

Links

PMC Free PDF

Authors+Show Affiliations

Dong Y
The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310058, China. Life Sciences Institute and Innovation Center for Cell Signaling Network, Hangzhou, 310058, China.
Dai T
Institutes of Biology and Medical Science, Soochow University, Suzhou, 215123, China.
Wei Y
Anhui Anlong Gene Technology Co., Ltd, Hefei, 230041, China.
Zhang L
Life Sciences Institute and Innovation Center for Cell Signaling Network, Hangzhou, 310058, China.
Zheng M
The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310058, China. minzheng@zju.edu.cn.
Zhou F
Institutes of Biology and Medical Science, Soochow University, Suzhou, 215123, China. zhoufangfang@suda.edu.cn.

MeSH

Angiotensin-Converting Enzyme 2Antibodies, ViralBetacoronavirusCOVID-19COVID-19 VaccinesClinical Trials as TopicCoronavirus InfectionsGene Expression RegulationHumansImmunity, InnateImmunization ScheduleImmunogenicity, VaccineMiddle East Respiratory Syndrome CoronavirusPandemicsPatient SafetyPeptidyl-Dipeptidase APneumonia, ViralProtein BindingReceptors, VirusSevere acute respiratory syndrome-related coronavirusSARS-CoV-2Severe Acute Respiratory SyndromeSpike Glycoprotein, CoronavirusVaccines, AttenuatedVaccines, DNAVaccines, SubunitVaccines, Virus-Like ParticleViral Vaccines

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Systematic Review

Language

eng

PubMed ID

33051445

Citation

Dong, Yetian, et al. "A Systematic Review of SARS-CoV-2 Vaccine Candidates." Signal Transduction and Targeted Therapy, vol. 5, no. 1, 2020, p. 237.
Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237.
Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., & Zhou, F. (2020). A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy, 5(1), 237. https://doi.org/10.1038/s41392-020-00352-y
Dong Y, et al. A Systematic Review of SARS-CoV-2 Vaccine Candidates. Signal Transduct Target Ther. 2020 Oct 13;5(1):237. PubMed PMID: 33051445.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A systematic review of SARS-CoV-2 vaccine candidates. AU - Dong,Yetian, AU - Dai,Tong, AU - Wei,Yujun, AU - Zhang,Long, AU - Zheng,Min, AU - Zhou,Fangfang, Y1 - 2020/10/13/ PY - 2020/7/10/received PY - 2020/9/27/accepted PY - 2020/9/6/revised PY - 2020/10/14/entrez PY - 2020/10/15/pubmed PY - 2020/11/6/medline SP - 237 EP - 237 JF - Signal transduction and targeted therapy JO - Signal Transduct Target Ther VL - 5 IS - 1 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that is highly pathogenic and has caused the recent worldwide pandemic officially named coronavirus disease (COVID-19). Currently, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Vaccines, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, have already entered clinical trials. In this review, we provide an overview of the experimental and clinical data obtained from recent SARS-CoV-2 vaccines trials, and highlight certain potential safety issues that require consideration when developing vaccines. Furthermore, we summarize several strategies utilized in the development of vaccines against other infectious viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), with the aim of aiding in the design of effective therapeutic approaches against SARS-CoV-2. SN - 2059-3635 UR - https://www.unboundmedicine.com/medline/citation/33051445/A_systematic_review_of_SARS_CoV_2_vaccine_candidates_ DB - PRIME DP - Unbound Medicine ER -